Request Demo
Recent blog posts
Latest Hotspot
8 min read
Laruparetigene zosaparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Laruparetigene zosaparvovec: Phase 2/3. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Fopitasvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Fopitasvir: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Upanovimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Upanovimab: Phase 2/3. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Etokimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Etokimab: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Daretabart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Daretabart: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Visugromab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Visugromab: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Livmoniplimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Livmoniplimab: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Mesutoclax Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Mesutoclax: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Danicamtiv Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Danicamtiv: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Choline bitartrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Choline bitartrate: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Cedazuridine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Cedazuridine: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Tebotelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Tebotelimab: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.